Menu
Cart
Book Cover

November-December 2018 NSDA Public Forum: Drug Price Controls

  • $ 16.00


PURCHASE AND DOWNLOAD RIGHT NOW!!

Big Sky Debate is pleased to release its November-December 2018 NSDA Public Forum resources on the drug price controls!

The resolution, released by the National Speech and Debate Association on October 1, 2018, is:

Resolved: The United States federal government should impose price controls on the pharmaceutical industry.

A list of briefs for this book appears below.

Continued this season: Get both the PDF and Word versions of the book. Copy and paste Big Sky Debate’s excellent research into your own briefs OR print and file the old-fashioned way!

Why choose Big Sky Debate over the competitors? We have one of the longest-standing Public Forum resource services in the nation.  Topic after topic, the Big Sky team delivers fresh, relevant and useful evidence and briefs for successful debate, no matter your location.

Download one brief, right now… don’t wait around for complex update services that are delivered after you are done with the topic!

Compare similar services without Big Sky Debate’s seasoned research staff at THREE times that cost! Big Sky Debate is the best value in debate!

Download one file, right now, with all the resources you need for this topic. Have a GREAT topic!!! Our Public Forum Resources are an unbeatable $16.00.

OR, click here to start a season-long subscription, or here to look at one of Big Sky Debate’s value-priced packages!  Start a subscription now and get the book in your inbox the moment we are done with our research!

 

Drug Price Control Index

PRO

  • PRICES TOO HIGH: PRICES ARE HIGH AND GETTING HIGHER
  • PRICES TOO HIGH: THEY CONTRIBUTE TO THE HEALTH CARE ACCESS ISSUES IN THE US
  • PRICES TOO HIGH: PATIENTS HURT WHEN SMALL MARKET DRUGS ARE PRICE-GOUGED
  • MUST ACT NOW
  • MARKETS DON’T SOLVE: WE DON’T HAVE A MARKET
  • CONTROLS BEST: FEDERAL OVERSIGHT NEEDED ON DRUG PRICING
  • CONTROLS BEST: IT IS THE ONLY COMPREHENSIVE SOLUTION
  • CONTROLS BEST: OUR CURRENT SYSTEM ALLOWS PRICE GOUGING
  • CONTROLS BEST: MUST TAKE OUTRAGEOUS PROFIT OUT OF THE DRUG MARKET
  • CONTROLS BEST: NEED STRATEGIES THAT PUT PATIENT NEEDS FIRST
  • CONTROLS BEST: INNOVATION SHOULD BE THROUGH GOVERNMENT RESEARCH AND PRIZE SCHEMES
  • CONTROLS BEST: CONTROL SCHEMES THAT FORCE REINVESTMENT DRIVE DOWN PRICES
  • CONTROLS BEST: AMERICANS SUPPORT
  • CURRENT EFFORTS FAIL: ALL ATTEMPTS PROTECT BIG PHARMA
  • CURRENT EFFORTS FAIL: MARKET PRESSURES HAVEN’T FIXED THE PROBLEM
  • CURRENT EFFORTS FAIL: TRUMP EXPORT RULES WON’T IMPACT PRICES
  • CURRENT EFFORTS FAIL: NO MEANINGFUL ACTION FROM TRUMP ADMINISTRATION
  • A/T: IMPORTING DRUGS IS BEST ALTERNATIVE
  • A/T: DEREGULATING DEVELOPMENT IS BEST ALTERNATIVE
  • A/T: LOWERING MANUFACTURING COSTS IS BEST ALTERNATIVE
  • A/T: CONTROLS STIFLE INNOVATION
  • A/T: EXPANDED GENERIC DRUGS WILL DRIVE DOWN PRICES
  • A/T: MARKET DEALING WITH ONE-OFF PRICE GOUGES (“PHARMA BRO”)
  • A/T: MARKETS ARE BEST 
  • A/T: MUST RECOUP RESEARCH COSTS
  • A/T: AMERICANS GET ACCESS TO NEW DRUGS

CON

  • CURRENT SYSTEM BEST: US DRUG ACCESS THE BEST IN THE WORLD, LEADING TO GOOD PATIENT OUTCOMES
  • CURRENT SYSTEM BEST: DRUGS ARE HIGH-VALUE PRODUCTS
  • PRICES REASONABLE: DRUG PRICES IN LINE WITH OTHER HEALTH CARE SPENDING
  • PRICES REASONABLE: MUST RECOUP RESEARCH COSTS
  • CONTROLS BAD: INEFFECTIVE, BAD POLICY
  • CONTROLS BAD: HURT BIOTECHNOLOGY INDUSTRY
  • CONTROLS BAD: DECREASE INCENTIVES FOR RESEARCH AND INNOVATION
  • CONTROLS BAD: UPSET CAREFUL BALANCE BETWEEN RIGHTS AND PATENTS
  • CONTROLS BAD: HURT PATIENTS DUE TO ACCESS
  • CONTROLS BAD: HURT PROGRESS MADE WITH GENERIC DRUGS
  • CONTROLS BAD: ALWAYS COST SOMEONE ELSE IN THE END
  • COMPETITION BETTER: DRUG PRICING STRATEGY MUST BE BASED ON COMPETITION
  • COMPETITION BETTER: MARKET-BASED SOLUTIONS DRIVE DOWN PRICES WHILE MAINTAINING ACCESS
  • COMPETITION BETTER: HEALTH CARE RESPONDS WELL TO COMPETITION
  • COMPETITION BETTER: GENERIC DRUG MOVEMENT PROVES
  • COMPETITION BETTER: MUST GIVE CONSUMERS CHOICES TO BEST FACILITATE MARKET FORCES
  • COMPETITION BETTER: MUST HAVE PRICE TRANSPARENCIES TO HELP MARKETS PERFORM
  • ALTERNATIVE: MAKE GENERIC APPROVAL PROCESS EASIER
  • ALTERNATIVE: ALLOW GOVERNMENT PROGRAMS THE ABILITY TO NEGOTIATE PRICES
  • ALTERNATIVE: DECREASE REGULATORY BARRIERS
  • A/T: PROFITING OFF OF NARROW-BAND DRUGS BAD (“PHARMA BRO” BAD)
  • A/T: SINGLE PAYER SCHEMES BEST
  • A/T: GOVERNMENT SUBSIDIES BAD
  • A/T: PRICES ARE TOO HIGH
  • A/T: OTHER COUNTRIES CONTROL PRICES
  • A/T: CURRENT NEED FOR ACCESS IS PARAMOUNT
  • A/T: MUST STICK IT TO DRUG COMPANIES

                      We Also Recommend